Found 143 clinical trials
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (DANBLOCK)
To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial infarction (MI) in patient with no heart failure reduces the composite outcome of death from any cause, recurrent MI, unstable angina pectoris, stroke or heart failure.
- 1 views
- 13 Mar, 2022
- 1 location
A Polypill for Secondary Prevention of Ischemic Heart Disease
because of an acute myocardial infarction (MI) (ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI)) will be randomized to either receiving Polypill or usual care after MI. Patient recruitment will be
- 10 views
- 26 Jan, 2021
- 2 locations
BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function (BETAMI)
The study aims to investigate whether oral betablocker (BB) therapy is superior to no such treatment following an acute myocardial infarction (AMI).
- 0 views
- 14 Feb, 2022
- 4 locations
Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
Long-term beta-blocker therapy has not been investigated in contemporary randomized clinical trials in patients with myocardial infarction and normal heart function. The aim of this study is to determine whether long-term treatment with oral beta-blockade in patients with myocardial infarction and preserved left ventricular systolic ejection fraction reduces the composite …
- 11 views
- 25 Apr, 2022
- 1 location
Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET) (MIMET)
Prediabetes is associated to an increased risk of cardiovascular disease and mortality. Although metformin can delay progression to diabetes there is a lack of RCTs evaluating the effect of metformin on cardiovascular outcomes. MIMET aims to investigate if addition of metformin to standard care has effects on the occurrence of …
- 0 views
- 23 Mar, 2022
- 1 location
ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO (ISCHEMIA-CTO)
> NSTEMI or STEMI within 1 month Coronary anatomy not suitable for CTO-procedure Coronary artery disease involving the left main/three-vessel disease with indication for CABG
- 56 views
- 22 Mar, 2022
- 15 locations
Very Early Versus Delayed Angiography +/- Intervention on Outcomes in Patients With NSTEMI (RapidNSTEMI)
Prospective, open, multicentre, randomised controlled trial in patients with higher risk non-ST elevation myocardial infarction acute coronary syndrome
- 2 views
- 26 Feb, 2022
- 1 location
Direct or Subacute Coronary Angiography in Patients With Out of Hospital Cardiac Arrest Without Coma.
In patients with Out-of-Hospital Cardiac arrest who achieves Return Of Spontaneous Circulation (ROSC) The investigators want to evaluate whether there is a benefit from acute Angiography compared to su bacute (12-24 hours) Angiography
- 0 views
- 16 May, 2021
- 1 location
Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack (DAPA-MI)
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for the prevention of hospitalisation for heart failure (HHF) or cardiovascular (CV) death.
- 8 views
- 03 Jul, 2022
- 91 locations
Beta Blocker Interruption After Uncomplicated Myocardial Infarction (AβYSS)
ABYSS is a national, multicenter, randomised, open label trial using the PROBE study design, that will evaluate the non-inferiority of the interruption of ΒB therapy after an uncomplicated MI after six months or more of follow-up compared to the continuation of βB evaluated by the primary endpoint or death, MI, …
- 77 views
- 05 Jul, 2022